Literature DB >> 7995324

A pharmacokinetic interaction between roxithromycin and midazolam.

J T Backman1, K Aranko, J J Himberg, K T Olkkola.   

Abstract

The interaction between roxithromycin and midazolam was investigated in a double-blind, randomised crossover study of two phases. Ten healthy volunteers were given roxithromycin (300 mg) or placebo once daily for 6 days. On the sixth day they ingested 15 mg midazolam. Plasma samples were collected and psychomotor performance measured for 17 h. Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 micrograms.ml-1.min and the elimination half-lives from 1.7 to 2.2 h. In psychomotor performance only minor differences were seen between the treatments in one of the measured psychomotor parameters. Thus, in contrast to the strong interaction between erythromycin and midazolam, the interaction between roxithromycin and midazolam appears less likely to be clinically significant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995324     DOI: 10.1007/BF00196114

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

2.  Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance.

Authors:  A N Griffiths; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

3.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

4.  Measurement of recovery from outpatient general anaesthesia with a simple ocular test.

Authors:  J G Hannington-Kiff
Journal:  Br Med J       Date:  1970-07-18

5.  A potentially hazardous interaction between erythromycin and midazolam.

Authors:  K T Olkkola; K Aranko; H Luurila; A Hiller; L Saarnivaara; J J Himberg; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

6.  Cimetidine and ranitidine increase midazolam bioavailability.

Authors:  J P Fee; P S Collier; P J Howard; J W Dundee
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

7.  A study of the interaction of roxithromycin with theophylline and carbamazepine.

Authors:  B Saint-Salvi; D Tremblay; A Surjus; M A Lefebvre
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  The usefulness of radioreceptor assay and gas liquid chromatography in pharmacokinetic studies on midazolam.

Authors:  L Aaltonen; J J Himberg; J Kanto; A Vuori
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-05

9.  Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.

Authors:  M J Mattila; J J Idänpään-Heikkilä; M Törnwall; J Vanakoski
Journal:  Pharmacol Toxicol       Date:  1993-09

Review 10.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

View more
  10 in total

1.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.

Authors:  Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

Review 2.  Macrolide antibiotics.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

Review 3.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 4.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

5.  General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.

Authors:  Sonja Krösser; Roland Neugebauer; Hugues Dolgos; Markus Fluck; Karl-Ludwig Rost; Andreas Kovar
Journal:  Eur J Clin Pharmacol       Date:  2006-03-07       Impact factor: 2.953

7.  A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.

Authors:  Akihiro Hisaka; Makiko Kusama; Yoshiyuki Ohno; Yuichi Sugiyama; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

9.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

10.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.